Oncoinvent CEO, Jan A. Alfheim will present the company at the DnB Nordic Healthcare Conference 2019 at the venture session for scaleups.

Oncoinvent CEO, Jan A. Alfheim will present the company at the Nordic American Life Science Conference in New York, USA 

Press Release 05.2019: Oncoinvent announced today that research relating to a radioactivity standard for radium-224 (224Ra) in secular equilibrium has been published in the Journal of Applied Radiation and Isotopes by Oncoinvent research scientist Elisa Napoli and researchers from the National Institute of Standards and Technology (NIST). This is an important step in the development of Radspherin® as the standard will form the basis for calibration of clinical doses of Radspherin®.

Oncoinvent would like to extend an invitation to a presentation of the Q3 2019 results. The presentation will be held at 14:00 on Thursday 31. October 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor. To attend, please register with  kvam@oncoinvent.com The quarterly report will be made available on www.oncoinvent.com on the 31. … Read more

CSO Tina Bønsdorff, presented the ePoster «Feasibility of Ra-224 SPECT CT imaging in a therapeutic setting – a phantom study» developed by Stokke (PhD, Assoc. Prof) and Mikalsen (PhD) at Oslo University Hospital, Oslo, NORWAY, at the European Association of Nuclear Medicine (EANM) annual conference held in Barcelona.

Oncoinvent would like to extend an invitation to a presentation of the Q2 2019 results. The presentation will be held at 15:00 on Thursday 29. August 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor. Going forward quarterly result presentations will be held on a regular basis. To attend, please register with kvam@oncoinvent.com … Read more

Oncoinvent researcher Elisa Napoli will present the poster “A primary activity standard for the alpha-emitting radionuclide Ra-224” at the SNMMI 2019 Annual Meeting.

Jan A. Alfheim, CEO of Oncoinvent will give a short status presentation about the company at the ABG Sundal Collier’s Norwegian Biotech Oncology Seminar

Oncoinvent CEO Jan A. Alfheim will be presenting the company during the International Cancer Cluster Showcase at the BIO International Convention 2019.

Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.